IGCS 2026 Early Career Workshop-Oral Abstract Presentations

Video Transcription

Video Summary

The afternoon research session featured presentations on several gynecologic oncology topics:

- <strong>Ovarian cancer and ctDNA:</strong> A small prospective study found that ultrasensitive circulating tumor DNA testing detected progression earlier and more sensitively than CA-125 during PARP inhibitor maintenance. Researchers said further studies are needed before using ctDNA to guide treatment.
- <strong>Early-stage ovarian cancer recurrence:</strong> A pooled analysis of six historical trials found recurrence risk was concentrated in the first five years and fell below 2% annually by year eight, supporting consideration of risk-adapted surveillance.
- <strong>Ovarian cancer in Nigeria:</strong> Findings from the Every Woman’s Study revealed delayed diagnosis, limited genetic testing and targeted treatment, and substantial financial burden. The data helped spur a national pilot initiative to improve awareness, diagnosis, and care.
- <strong>Hormone therapy in BRCA carriers:</strong> Survey results showed that education and relationship status influenced premenopausal women’s views on hormone replacement therapy, while age and prior contraceptive use were associated with actual use after menopause.
- <strong>Cervical cancer brachytherapy:</strong> A propensity-matched study found interdigitated treatment had outcomes and late toxicity comparable to sequential brachytherapy, while helping protect timely completion of treatment.

The session concluded with audience discussion and awards for three projects in the Pragmatic Trials competition.

Keywords

gynecologic oncology

ovarian cancer

ctDNA

PARP inhibitor maintenance

early-stage recurrence

Nigeria

BRCA carriers

hormone replacement therapy

cervical cancer brachytherapy